Latest Healthcare It News

Arena REIT has declared its June 2026 quarterly distribution at 4.8125 cents per security, consistent with its full-year guidance, and is offering a Dividend Reinvestment Plan with a 1.5% discount to encourage reinvestment.

InteliCare (ASX:ICR) is hitting a commercial inflection point, backed by a landmark $8.8 million contract with mecwacare and a growing pipeline across aged care sectors. Its AI-powered platform promises measurable improvements in care outcomes and operational efficiency.

Charter Hall Social Infrastructure REIT (CQE) has acquired a 25% interest in a $53 million Brisbane pathology lab leased to Sonic Healthcare under a 20-year triple-net lease, while divesting early learning assets and reaffirming FY26 guidance.

Microba Life Sciences secures $5 million in a placement led by Sonic Healthcare to fund its push towards cashflow break-even by 2027, backed by strong diagnostic sales and AI-driven efficiencies.

TruScreen has secured clinical validation from the world’s largest cervical screening study in China, setting the stage for rapid market expansion across Asia, Africa, and Europe.

Kingfish Limited's May update reveals a robust 5.5% portfolio return, driven by standout performances from Fisher & Paykel Healthcare and Infratil amid mixed sector headwinds.

EBR Systems has kicked off a fully underwritten 1-for-2 entitlement offer priced at $0.38 per CDI, aiming to raise $85.6 million to accelerate commercialisation and manufacturing of its wireless cardiac pacing technology.

LTR Pharma has locked in Strive Specialties as its exclusive US pharmacy fulfilment partner for ROXUS, marking a critical step towards commercial launch in the US erectile dysfunction market.

dorsaVi has secured exclusive rights to two key robotics patents from NTU Singapore, filling critical gaps in safety control and data acquisition to expand into collaborative robotics and exoskeleton markets.

Elanor Investors Group has finalised a $125 million recapitalisation that slashes its cost of capital and reduces debt, setting the stage for a leaner, capital-light funds management model and imminent ASX reinstatement.

LTR Pharma has secured a binding US telehealth commercialisation framework for its intranasal erectile dysfunction treatment ROXUS, committing to at least 150,000 prescriptions in the first year and granting exclusivity to Shed Holdings' platform.

Ryman Healthcare has opened a NZ$100 million fixed rate bond offer maturing in 2032, featuring an exchange mechanism for existing bondholders and a minimum interest rate of 5.60%. The offer targets institutional and retail investors and aims to refinance debt and diversify funding.